

Hyloris' Annual General Shareholders Meeting was Held Today Communication of the 2024 Half-Year Results will be Delayed

- Ms. Revital Rattenbach and Mr. Vincent Van Dessel Appointed as New Independent Directors
- 2024 Half-Year Results Expected to be Announced at the Latest on Friday, 4th of October
 2024

Liège, Belgium - 30 September 2024 – 10.30 PM CET - Regulated Information – Inside Information - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it held its Annual General Meeting (AGM)¹ at its headquarters, initially planned to 11th of June 2024.

Hyloris is pleased to announce the appointment of Ms. Revital Rattenbach and Mr. Vincent Van Dessel as new independent Directors, along with the reappointment of Mr. Marc Foidart as an independent Director.

Mr. Thomas Jacobsen (Co-CEO of Hyloris) mentioned: 'We are confident that the expertise and value the independent Directors will bring, combined with the experience of the other Directors which have been reappointed, will support Hyloris in further enhancement of its operations, especially in the areas of internal governance and compliance."

Shareholders present or represented at the AGM accounted for 59.40% of the company's shares. The meeting was attended by shareholders both physically and by proxy.

The release of the 2024 half-year results will be delayed and is now expected no later than October 4th, 2024. While the audit of the 2024 half-year results is nearly complete, the company, in consultation with the auditor, is still assessing the potential impact on its financial statements regarding the recovery of 50% of the AltaThera litigation costs from our development partner, following the recent decision by the American Arbitration Association on September 13th, 2024.

About Hyloris Pharmaceuticals

The Company's development strategy primarily focuses on leveraging established regulatory pathways, such as the FDA's 505(b)2 pathway in the U.S or equivalent regulatory frameworks in other regions which are specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This approach can reduce the clinical burden required for market entry, and significantly shorten the development timelines, leading to reduced costs and risks.

Hyloris has built a broad, patented portfolio of 19 reformulated and repurposed value-added medicines that have the potential to offer significant advantages over existing alternatives. Two products are currently in early phases of commercialization in collaboration with commercial partners:

¹ See: https://hyloris.com/second-general-assembly-2024/



_

Press Release Regulated Information – Inside Information



Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. In addition to its core strategic focus, the Company has 1 approved high barrier generic product launched in the U.S. and 2 high barrier generic products in development.

Hyloris is based in Liège, Belgium. For more information, visit <u>www.hyloris.com</u> and follow-us on <u>LinkedIn</u>.

For more information, contact Hyloris Pharmaceuticals:

Stijn Van Rompay, co-CEO stijn.vanrompay@hyloris.com +32 (0)4 346 02 07 Thomas Jacobsen, co-CEO thomas.jacobsen@hyloris.com +32 (0)4 346 02 07

Disclaimer and forward-looking statements

Hyloris means "high yield, lower risk", which relates to the 505(b)(2) regulatory pathway for product approval on which the Company focuses, but in no way relates or applies to an investment in the Shares.

Certain statements in this press release are "forward-looking statements." These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company's control, that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

